<DOC>
	<DOC>NCT02812394</DOC>
	<brief_summary>This study will be an open-label, randomized, three-period cross-over pharmacokinetic evaluation of CVT-301 compared with the Reference Listed Drug (RLD), orally administered carbidopa/levodopa, in healthy volunteers.</brief_summary>
	<brief_title>A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of SinemetÂ® (Carbidopa-levodopa) Tablets</brief_title>
	<detailed_description>The primary objective is to determine the relative bioavailability of two CVT-301 (dose levels 1 and 2) capsules compared with the Reference Listed Drug (RLD) on a per milligram basis.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa, levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>In good general health as determined by medical history, physical examination, electrocardiogram (ECG), vital signs, and clinical laboratory evaluation; FEV1/FVC above the 5th percentile of the predicted normal distribution for age and gender; Body Mass Index (BMI) between 18 30 kg/m2 No flulike syndrome or other respiratory infections within 2 weeks prior to the Screening Visit; Negative drug and alcohol testing; Negative pregnancy test for female subjects</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Parkinson's disease</keyword>
	<keyword>Episodic motor fluctuations (OFF periods)</keyword>
</DOC>